- Home
- REVB vs AVX Comparison
REVB vs AVX Comparison
Compare REVB & AVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVB
- AVX
- Stock Information
- Founded
- REVB 2020
- AVX 2017
- Country
- REVB United States
- AVX Canada
- Employees
- REVB N/A
- AVX N/A
- Industry
- REVB Biotechnology: Pharmaceutical Preparations
- AVX Metal Fabrications
- Sector
- REVB Health Care
- AVX Industrials
- Exchange
- REVB Nasdaq
- AVX Nasdaq
- Market Cap
- REVB 2.3M
- AVX 2.4M
- IPO Year
- REVB N/A
- AVX 2021
- Fundamental
- Price
- REVB $0.85
- AVX $1.50
- Analyst Decision
- REVB
- AVX
- Analyst Count
- REVB 0
- AVX 0
- Target Price
- REVB N/A
- AVX N/A
- AVG Volume (30 Days)
- REVB 118.3K
- AVX 382.0K
- Earning Date
- REVB 11-06-2025
- AVX 11-14-2025
- Dividend Yield
- REVB N/A
- AVX N/A
- EPS Growth
- REVB N/A
- AVX N/A
- EPS
- REVB N/A
- AVX N/A
- Revenue
- REVB N/A
- AVX $1,319,011.00
- Revenue This Year
- REVB N/A
- AVX N/A
- Revenue Next Year
- REVB N/A
- AVX N/A
- P/E Ratio
- REVB N/A
- AVX N/A
- Revenue Growth
- REVB N/A
- AVX 8001.54
- 52 Week Low
- REVB $0.84
- AVX $1.45
- 52 Week High
- REVB $60.48
- AVX $41.31
- Technical
- Relative Strength Index (RSI)
- REVB 24.56
- AVX N/A
- Support Level
- REVB $0.84
- AVX N/A
- Resistance Level
- REVB $1.08
- AVX N/A
- Average True Range (ATR)
- REVB 0.08
- AVX 0.00
- MACD
- REVB -0.01
- AVX 0.00
- Stochastic Oscillator
- REVB 5.77
- AVX 0.00
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).